NCT05987644 2026-03-09
DURABLE
Hoosier Cancer Research Network
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT04774718 2026-03-06
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT03202940 2025-09-25
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Massachusetts General Hospital
Phase 1/2 Active not recruiting
NCT05713006 2025-05-01
Alectinib Pharmacokinetic in Patients With NSCLC
Instituto Nacional de Cancerologia de Mexico
Phase 1/2 Recruiting
NCT03158389 2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2 Completed
NCT03131206 2021-09-27
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT01801111 2018-11-02
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Hoffmann-La Roche
Phase 1/2 Completed